Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions

Table 3 Prevalence of high-risk human papillomavirus genotypes according to the vaccine-targeted high-risk human papillomavirus genotypes

		Total
		n = 595	%	95%CI
Regarding HPV genotype
No high-risk^a		160	26.89	23.24	30.54
At least 1 high-risk		435	73.11	69.46	76.76
According to the vaccine-targeted high-risk HPV genotypes
No high-risk^a		160	26.89	23.24	30.54
Quadrivalent HPV non-vaccine-targeted high-risk HPV genotypes^b		229	38.49	34.49	42.48
	Quadrivalent HPV and nine-valent HPV non-vaccine-targeted high-risk HPV genotypes^c	107	17.98	14.81	21.15
	Additional five high-risk HPV genotypes present in the nine-valent HPV vaccine^d	122	20.50	17.18	23.83
Vaccine-targeted high-risk HPV genotypes (16 or 18)		201	33.78	29.90	37.67
Vaccine-targeted high-risk HPV genotypes (16 and 18)		5	0.84	0.27	1.95

^aNo high-risk. Classification human papillomavirus (HPV) types according to the World Health Organization International Agency for Research on Cancer (IARC) Monographs Working Group assessment of the carcinogenicity of different HPV types [25,26,27]
^bAt least 1 of the quadrivalent HPV non-vaccine-targeted high-risk HPV genotypes (31 or 33 or 35 or 39 or 45 or 51 or 52 or 56 or 58 or 59 or 68)
^cAt least 1 of the quadrivalent HPV and nine-valent HPV non-vaccine-targeted high-risk HPV genotypes (35 or 39 or 51 or 56 or 59 or 68)
^dAt least 1 of the additional five high-risk HPV genotypes present in the nine-valent HPV vaccine (31 or 33 or 45 or 52 or 58)

ISSN: 1471-2407